Protagonist Therapeutics (NASDAQ:PTGX) Given a $23.00 Price Target by HC Wainwright Analysts

Protagonist Therapeutics (NASDAQ:PTGX) received a $23.00 target price from research analysts at HC Wainwright in a research note issued on Friday, TipRanks reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 135.41% from the stock’s current price.

A number of other research analysts also recently weighed in on PTGX. ValuEngine downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $11.00 to $17.00 in a report on Wednesday, May 8th. Finally, BidaskClub downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $17.17.

Shares of Protagonist Therapeutics stock traded down $0.28 during midday trading on Friday, reaching $9.77. 10,525 shares of the company’s stock traded hands, compared to its average volume of 193,296. The stock has a market capitalization of $242.15 million, a P/E ratio of -5.61 and a beta of 1.87. The firm has a 50 day moving average of $12.21. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.02 and a current ratio of 5.02. Protagonist Therapeutics has a 52 week low of $5.49 and a 52 week high of $14.36.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.01. The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $2.50 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 40.78%. As a group, research analysts expect that Protagonist Therapeutics will post -2.07 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Bank of Montreal Can grew its stake in Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after buying an additional 10,405 shares during the last quarter. D. E. Shaw & Co. Inc. grew its position in Protagonist Therapeutics by 75.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after purchasing an additional 8,450 shares during the last quarter. Bank of America Corp DE grew its position in Protagonist Therapeutics by 94.3% in the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after purchasing an additional 12,819 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in Protagonist Therapeutics in the 1st quarter worth $410,000. Finally, Northern Trust Corp grew its position in Protagonist Therapeutics by 17.2% in the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after purchasing an additional 5,084 shares during the last quarter. Institutional investors and hedge funds own 64.39% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Read More: P/E Growth (PEG)

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.